Company: CSDX
Filing Date: 2025-10-09
Form Type: 10-Q
Source: 0001214659-25-014817
Chunk: 8

Company: CS DIAGNOSTICS CORP.
Filing Date: 2025-10-09
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
 the Company’s
disclosure controls and procedures were effective as of June 30, 2025 in ensuring that information required to be disclosed by the Company
in the reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods
specified in the SEC’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the PEO
and PFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

The Company also carried out an evaluation, under the supervision and
with the participation of management, including the PEO and PFO, of changes in the Company’s internal control over financial reporting
(as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended June 30, 2025.

There were no changes in our internal control over financial reporting
during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.

Forward-Looking Statements

This MD& A contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current
expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors
that could cause such differences include, among others, those discussed under “ Risk Factors” in Part II, Item 1A of this
Report.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

As of the date of this Report, the Company is involved in the following
legal proceedings:

CS Diagnostics Corp. v. Wilson, U. S. District Court, Northern District
of Texas (Dallas), Case No. 3:25-cv-01158-N

In May 2025, the Company initiated a civil action in the United States
District Court for the Northern District of Texas against a minority shareholder who allegedly sold a substantial volume of CSDX stock
after previously representing a long-term investment intent. The Company believes that these sales contributed to a decline in its stock
price and negatively impacted investor confidence and potential business relationships. The complaint seeks damages and equitable relief.
As of the date of this Report, the matter remains in the jurisdictional-discovery phase.

CS Diagnostics Corp